• DISCOVERY

    A Thriving Environment for Biomedical Discovery

  • Noel Warfel, PhD

    Modeling the Effects of Hypoxia on Cancer Cells and Tumor Angiogenesis

  • RESEARCH

    An Established Leader in Cutting-edge Research

  • Curtis Thorne, PhD

    Discovering Signals Controlling Cell Fate of Regenerative Tissues

  • Gus Mouneimne, PhD

    Understanding How Cytoskeletal Architecture Regulates Cancer Metastasis

  • Greg Rogers, PhD

    Investigating Mechanisms of Genomic Integrity

  • Jean Wilson, PhD

    Cell biology of barrier function in inflammatory bowel diseases

  • LEADERS

    Training Our Next Leaders in Biomedical Research

  • Casey Romanoski, PhD

    Systems Genetics Approaches to Identify Mechanisms of Complex Diseases

  • Tom Doetschman, PhD

    Synergistic Activities of TGFbeta Deficiency and the Gut Microbiome in Colon Cancer

Home

Message from the Chair

The mission of the Department of Cellular and Molecular Medicine (CMM) is to provide pre- and post-doctoral, medical and graduate education in an interdisplinary environment through research activities, to advance knowledge of biological structure as related to function and disease from the molecular level to the whole organism.

Announcements

Congratulations to CMM students named UA ARCS Foundation Scholars for 2018-2019 (February 23, 2018)

Cellular & Molecular Medicine PhD students John Ryniawec and Kelvin Pond have been selected as UA ARCS Foundation scholars for 2018-2019!  This award consists of a $10,5000 cash scholarship, a $500 travel grant and full base tuition.  Congratulations, John and Kelvin!

Professor Gregory Rogers, PhD, awarded $1.2 million NIH R01 grant to study centrosome function and duplication (February 23, 2018)

Congratulations to Gregory Rogers, PhD, who was recently awarded a 4 year, $1.2 million grant from the Nation Institute of General Medicine Sciences (NIGMS). His grant entitled “Inherent mechanism that govern centrosome function and duplication” focuses on dissecting evolutionarily conserved mechanisms that control the behaviors of centrosomes -- processes that, when dysfunctional, contribute to ciliopathy, birth defects and tumorigenesis.

Professor Henk Granzier, PhD, and Granzier Lab featured in UA News article (November 14, 2017)

Congratulations to CMM professor Henk Granzier, PhD, and the Granzier Lab, who were featured in an article for UA News!  The article focuses on the Granzier Lab's discovery that titin regulates thick filament length in striated muscle.  "Functionally and clinically, it is very important to regulate the thick filament precisely, otherwise muscles would not function well," said Dr. Granzier. "Biologists have always wondered what makes them so precisely structured."  https://uanews.arizona.edu/story/introducing-titin-protein-rules-our-hea...

The Granzier Lab's findings were recently published in Nature Communications: https://www.nature.com/articles/s41467-017-01144-9

Assistant Professor Casey Romanoski, PhD, to present at 2017 American Society of Human Genetics Meeting (November 8, 2017)

Congratulations to CMM Assistant Professor Casey Romanoski, PhD, as she was selected to showcase her lab's research at the 2017 American Society of Human Genetics meeting in Orlando, FL.  The Romanoski Lab is using genetic differences between people's vascular cells to better define the cellular mechanisms that explain why some people are more prone to develop vascular diseases.

Warfel Lab published in Clinical Cancer Research (November 8, 2017)

In recent study led by CMM Assistant Professor Noel Warfel, PhD, researchers identified PIM kinase expression as a novel mechanism of resistance to anti-angiogenic agents. Using models of prostate and colon cancer, they show that PIM is upregulated following treatment with anti-angiogenic therapies, which reduces the ability of these drugs to disrupt tumor vasculature. Moreover, combined inhibition of PIM and VEGF produces a synergistic anti-tumor response characterized by decreased proliferation, reduced tumor vasculature, and reduced metastasis. These findings, published in Clinical Cancer Research, show that targeting PIM kinase activity is a promising strategy to combat hypoxia-mediated therapeutic resistance. http://clincancerres.aacrjournals.org/content/early/2017/10/28/1078-0432.CCR-17-1318

Upcoming Events

Apr
12
CMM Joint Seminar: Dave Washaw
Thursday 4:00pm to 5:00pm
Sarver Heart Center 4137

Apr
19
CMM Joint Seminar: Konstantin Doubrovinski
Thursday 4:00pm to 5:00pm
TBD

May
03
CMM Joint Seminar: Sanaz Memarzadeh
Thursday 4:00pm to 5:00pm
TBD